לחברי האיגוד הישראלי לקרישת הדם שלום,

אנחנו מבצעים סקר בנושא הגישה לניהול הטיפול האנטיטרומבוטי בחולים עם טרומבוציטופניה. הסקר נעשה בשיתוף פעולה עם עמיתים מהולנד ואיטליה.
הסקר מבוסס על 8 מקרים קליניים ומילוי הסקר אמור להיערך כ 15 דקות.
נודה לכם אם תואילו בטובכם להשתתף בסקר על ידי קריאת המכתב שמופיע בהמשך וכניסה לקישור הזה.

תודה רבה על עזרתכם במחקר שלנו ועל שיתוף הפעולה.

בברכה,
ד"ר אבי לידר
ד"ר גליה ספקטר

Dear friends and colleagues,

We are undertaking a survey aimed at identifying the decision-making process employed when managing pre-existing antithrombotic therapy among patients with hematological disorders who develop thrombocytopenia. This scenario is not uncommon and the little that is known pertains specifically to LMWH in venous thromboembolism. The drivers behind management decisions have not been researched.
In order to address this issue, we have designed a survey that contains 8 case vignettes and takes about 15 minutes to complete. The survey is anonymous. There is no right or wrong answer. To begin the questionnaire please click on the following link.
(In the event that this website is blocked by your institutional computer blocks, please try another computer, smartphone or tablet/iPad).

Please answer this questionnaire if you are a hematologist (including residents/fellows) and/or a specialist in thrombosis and hemostasis and/or a specialist in transfusion medicine, and involved in management decisions for such patients. Also, if you would like, please pass the email and survey link on to relevant colleagues.
This project is not sponsored by pharmaceutical companies and as such we are unable to offer an incentive to complete it, but the results of the survey will demonstrate the drivers behind management of these patients and will assist in planning prospective trials evaluating management strategies of this complex scenario.
Many thanks for taking time to read this. Your participation will be much appreciated, preferably within the next month.

Yours Sincerely,
Avi Leader MD, Maastricht University Medical Center, the Netherlands and Rabin Medical Center, Israel
Hugo ten Cate, MD PhD, Maastricht University Medical Center, the Netherlands
Harry Schouten MD, Maastricht University Medical Center, the Netherlands
Galia Spectre, MD, PhD Rabin Medical Center, Israel
Anna Falanga MD, Hospital Papa Giovanni XXIII Bergamo, Italy